Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

Vincenza Conteduca,Sheng-Yu Ku,Luisa Fernandez,Angel Dago-Rodriquez,Jerry Lee,Adam Jendrisak,Megan Slade,Cole Gilbertson,Jyothi Manohar,Michael Sigouros,Yipeng Wang,Ryan Dittamore,Rick Wenstrup,Juan Miguel Mosquera,Joseph D. Schonhoft,Himisha Beltran
DOI: https://doi.org/10.1038/s41698-021-00211-1
2021-08-12
npj Precision Oncology
Abstract:Abstract Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.
oncology
What problem does this paper attempt to address?